Results 181 to 190 of about 37,681 (214)
Some of the next articles are maybe not open access.
Terazosin for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews, 2000Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker ...
T J, Wilt +3 more
openaire +2 more sources
Medicina Clínica (English Edition)
Benign prostatic hyperplasia (BPH) is a histopathologic definition associated with enlargement of the prostate gland that causes obstruction of the lower urinary tract and manifests clinically with characteristic symptoms that are what bring patients for consultation.
Sarelis, Infante Hernández +2 more
openaire +2 more sources
Benign prostatic hyperplasia (BPH) is a histopathologic definition associated with enlargement of the prostate gland that causes obstruction of the lower urinary tract and manifests clinically with characteristic symptoms that are what bring patients for consultation.
Sarelis, Infante Hernández +2 more
openaire +2 more sources
Phytotherapy for Benign Prostatic Hyperplasia
Current Urology Reports, 2016The use of complementary and alternative medications for symptomatic benign prostatic hyperplasia is a lucrative business in the USA with revenues reaching close to US$6.4 billion in sales for the 2014 fiscal year. Yet, despite its popularity, the evidence supporting the continued use of phytotherapy for symptomatic benign prostatic hyperplasia (BPH ...
Aryeh, Keehn +2 more
openaire +2 more sources
Benign prostate hyperplasia and nutrition
Clinical Nutrition ESPEN, 2019and aims: Benign Prostatic hyperplasia (BPH) is an important public health problem. Roughly half of all men will suffer from BPH related symptoms later in life. The prostate gland, a hormone dependent part of the male reproductive system, is susceptible to internal and external disruptions of regulatory systems.
K, Das, N, Buchholz
openaire +2 more sources
Exophytic Benign Prostatic Hyperplasia
Urology, 2011A 60-year-old man had incidental finding of a multilobular 8 × 7 × 7-cm mass identified posterior to the urinary bladder in continuity with the prostate. The man's prostate-specific antigen was 1.87, and he denied any lower urinary tract symptoms. A transrectal ultrasound-guided biopsy demonstrated benign prostatic tissue.
Sarah D, Blaschko, Michael L, Eisenberg
openaire +2 more sources
Investigation of benign prostatic hyperplasia
Current Opinion in Urology, 2003This is a concise and timely update of the most recent developments in the clinical research on the investigation of benign prostatic hyperplasia.Analysis of the peer-review literature confirms a high level of consensus as to the management of prostatic hyperplasia; analysis of practice trends suggests a satisfactory degree of adoption of the proposed ...
TUBARO, ANDREA +2 more
openaire +3 more sources
Management of Benign Prostatic Hyperplasia
Annual Review of Medicine, 2016Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development.
Eric H, Kim +2 more
openaire +2 more sources
Finasteride for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews, 2009Benign prostatic hyperplasia (BPH), a non-malignant enlargement of the prostate in aging men, can cause bothersome urinary symptoms (intermittency, weak stream, straining, urgency, frequency, incomplete emptying). Finasteride, a five-alpha reductase inhibitor (5ARI), blocks the conversion of testosterone to dihydrotestosterone, reduces prostate size ...
James, Tacklind +4 more
openaire +2 more sources
Cernilton for benign prostatic hyperplasia
Cochrane Database of Systematic Reviews, 1998Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily.
T, Wilt +4 more
openaire +2 more sources
Etiology of Benign Prostatic Hyperplasia
European Urology, 1994The natural history of benign prostatic hyperplasia (BPH) involves two phases. The first, or pathologic phase, is composed of two stages, microscopic and macroscopic, neither of which produces symptomatic clinical dysuria. Nearly all men throughout the world eventually develop microscopic BPH if they live long enough. In only about 50% of men, however,
openaire +2 more sources